Tirzepatide: FDA records on compounded and unapproved products
Has FDA taken action on compounded tirzepatide?
Yes. As of Nov 15, 2026, FDA has issued 111 warning letters to 109 companies whose text names tirzepatide, the latest dated Oct 30, 2026, and openFDA lists 28 recall reports naming it. FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list (statement dated Apr 1, 2026).
As of Nov 15, 2026, FDA’s drug shortage data lists no tirzepatide products.
What FDA has stated, by date
- Oct 2, 2024: FDA announced it had determined that the shortage of tirzepatide injection was resolved. In October 2024 that decision was remanded to FDA for reevaluation as part of litigation. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Dec 19, 2024: After reevaluating, FDA issued a new decision that the tirzepatide injection shortage is resolved. FDA said it did not intend to take action, for violations that depend on tirzepatide being on the shortage list, against state-licensed pharmacies (section 503A) until February 18, 2025, or outsourcing facilities (section 503B) until March 19, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Mar 5, 2025: A federal district court denied the preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.). FDA stated (update dated March 10, 2025) that the enforcement discretion period for 503A tirzepatide compounding had ended, and that for 503B outsourcing facilities it ran until March 19, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Sep 5, 2025: FDA established a “green list” import alert (Import Alert 66-80) for GLP-1 active pharmaceutical ingredients. APIs from facilities on the list may enter; APIs from other sources are subject to detention without physical examination. Source: FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA restated the section 503A conditions: compounding for an individual patient on a prescription, and not compounding regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug. FDA gave semaglutide combined with vitamin B12 (cyanocobalamin) as an example that may be considered essentially a copy, and said that at this time it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- May 1, 2026: The proposal was published in the Federal Register (Docket No. FDA-2018-N-3240, 91 FR 23431) with comments due June 30, 2026. Source: Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Jun 26, 2026: FDA extended to July 30, 2026 the comment period on its proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. Source: Federal Register, June 26, 2026: Extension of Comment Period
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
FDA drug shortage status
No tirzepatide entries in FDA’s drug shortage data as of Nov 15, 2026.
Shortage history, by date
| FDA’s words or record | Source | ||
|---|---|---|---|
| Dec 15, 2022 | Listed | “Tirzepatide injection products were first added to FDA’s drug shortage list on December 15, 2022.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| April 2024 | Listed | “The Zepbound pen products were approved by FDA in November 2023 (NDA 217806) and added to FDA’s drug shortage list in April 2024 due to high demand.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Oct 2, 2024 | Resolved | “The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Oct 22, 2024 | Litigation | “As part of litigation, the decision to remove tirzepatide from the FDA drug shortage list has been remanded to the agency for reevaluation.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Dec 19, 2024 | Resolved | “This order revokes and replaces FDA’s October 2, 2024 decision on the same subject. I. Determination FDA determines that the tirzepatide injection product shortage is resolved.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Feb 18, 2025 | 503A grace period end | “For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until February 18, 2025” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Mar 5, 2025 | Litigation | “On March 5, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.).” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Mar 19, 2025 | 503B grace period end | “For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until March 19, 2025.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Apr 1, 2026 | Status statement | “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
All GLP-1 drugs on one timeline: shortage history.
FDA adverse event reports (FAERS) listing tirzepatide
openFDA’s copy of FDA’s adverse event database holds 181,257 reports that list tirzepatide, received from Jul 28, 2015 through Sep 30, 2026. 33,215 (18%) are marked serious by the reporter, including 1,052 that list death as an outcome. 189 reports name a compounded or combination tirzepatide product in the product fields. These are unverified reports and do not show that the drug caused any event.
FAERS reports are sent to FDA by drug makers, health professionals and the public. FDA does not verify them, a report does not show that the drug caused the event, and the same event can be reported more than once. Counts reflect how often events were reported, not how often they happen or how risky a drug is. Nothing here is medical advice. Report an error or add a company response.
Reports by year FDA received them
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 28 |
| 2020 | 33 |
| 2021 | 38 |
| 2022 | 5,052 |
| 2023 | 20,806 |
| 2024 | 33,068 |
| 2025 | 62,369 |
| 2026 | 59,845 |
Reaction terms listed most often
| Incorrect dose administered | 32,160 | 17.7% |
| Nausea | 19,760 | 10.9% |
| Injection site pain | 14,622 | 8.1% |
| Diarrhoea | 11,332 | 6.3% |
| Extra dose administered | 10,288 | 5.7% |
| Off label use | 10,042 | 5.5% |
| Vomiting | 9,422 | 5.2% |
| Drug ineffective | 8,301 | 4.6% |
| Constipation | 7,630 | 4.2% |
| Fatigue | 5,711 | 3.2% |
A report can list several reaction terms. Terms such as “Off label use” or “Incorrect dose administered” describe how the drug was used, not a bodily reaction.
Reports naming a compounded or combination tirzepatide product
In openFDA’s public copy of FDA’s adverse event data, checked Nov 15, 2026, 189 reports of the 181,257 listing tirzepatide have product text that identifies a compounded or combination product: 188 list tirzepatide combined with a vitamin or amino acid such as cyanocobalamin (vitamin B12), and 1 use the word “compounded” or “compound” in the product name or dosage text. The public data has no compounded flag and no narrative, so this is a floor, not a full count, and the reports are unverified. More on the compounded tirzepatide reports page.
A report is counted as naming a compounded product only when one drug entry in it names the drug and that same entry either uses the word “compounded”, “compounding” or “compound” in its product name or dosage text, or lists the drug together with cyanocobalamin, methylcobalamin, pyridoxine, glycine, levocarnitine, carnitine, niacinamide or vitamin B12 or B6 in one product name, a combination no FDA-approved product of these drugs contains. openFDA’s public data has no field that marks a product as compounded and leaves out the report narrative, so this finds only reports whose product text shows it. FDA’s own counts for compounded semaglutide and tirzepatide, from its full internal data, are higher.
| Report | |||||
|---|---|---|---|---|---|
| Sep 30, 2026 | CYANOCOBALAMIN\NADIDE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27328171 |
| Sep 24, 2026 | CYANOCOBALAMIN\GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27310876 |
| Sep 22, 2026 | CYANOCOBALAMIN\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27291966 |
| Sep 22, 2026 | GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27297319 |
| Sep 19, 2026 | PYRIDOXINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27286507 |
| Sep 18, 2026 | GLP1 Tirzepatide/Niacinamide | Combined with a vitamin or amino acid | Concomitant | Yes | openFDA 27278464 |
| Sep 17, 2026 | NIACINAMIDE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27272866 |
| Sep 14, 2026 | CYANOCOBALAMIN\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27254934 |
| Sep 14, 2026 | GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27259804 |
| Sep 11, 2026 | LEVOCARNITINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27243278 |
| Sep 11, 2026 | CYANOCOBALAMIN\GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27248058 |
| Sep 10, 2026 | GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27242594 |
| Sep 8, 2026 | LEVOCARNITINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27231004 |
| Sep 6, 2026 | LEVOCARNITINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27227103 |
| Sep 5, 2026 | PYRIDOXINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27226022 |
| Sep 3, 2026 | TIRZEPATIDE | Product text says compounded | Suspect | Yes | openFDA 27205951 |
| Sep 3, 2026 | PYRIDOXINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27212705 |
| Sep 2, 2026 | CYANOCOBALAMIN\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27208032 |
| Sep 1, 2026 | PYRIDOXINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27197290 |
| Sep 1, 2026 | CYANOCOBALAMIN\GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27202230 |
| Aug 31, 2026 | GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27196091 |
| Aug 27, 2026 | GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27183302 |
| Aug 26, 2026 | GLYCINE\METHYLCOBALAMIN\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27174054 |
| Aug 26, 2026 | METHYLCOBALAMIN\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27177831 |
| Aug 24, 2026 | GLYCINE\TIRZEPATIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27167056 |
The 25 most recent are shown; all 189 are on the adverse event reports page.
Active ingredient (API) imports: FDA import alert and refusal records
FDA’s Import Alert 66-80 Green List (published Oct 9, 2026) has 9 entries naming tirzepatide, in China (8) and Canada (1); FDA redacts the firm names. FDA’s import refusal records list 201 refused shipment lines whose product code names tirzepatide, from Aug 30, 2023 to Oct 29, 2026, most often from Canada (39), United States (32) and United Kingdom (27); 21 carry an API or powder product code listed on the alert.
Import Alert 66-80 Green List entries naming tirzepatide
| Product codes and drugs listed | |||
|---|---|---|---|
| 2 | Redacted by FDA | CANADA | 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 5 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 6 | Redacted by FDA | CHINA | 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 7 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 8 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 10 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 11 | Redacted by FDA | CHINA | 61P[][]74 Tirzepatide (Anti-Diabetic) 61P[][]77 Orforglipron (Anti-Diabetic) |
| 12 | Redacted by FDA | CHINA | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 13 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
Refused tirzepatide lines by country and form
| Canada | 39 |
| United States | 32 |
| United Kingdom | 27 |
| China | 21 |
| India | 18 |
| Italy | 12 |
| Japan | 9 |
| Netherlands | 7 |
| France | 6 |
| Turkey | 6 |
| Bangladesh | 5 |
| Hong Kong | 3 |
| Vietnam | 3 |
| Colombia | 2 |
| Germany | 2 |
| Lithuania | 2 |
| Switzerland | 2 |
| Australia | 1 |
| Paraguay | 1 |
| Philippines | 1 |
| Portugal | 1 |
| United States Outlying Islands | 1 |
| Code not listed on Import Alert 66-80 | 180 |
| Active Pharm Ingred/Chems for Rx Compounding | 9 |
| Sterile Powder | 6 |
| NonSterile Powder | 5 |
| Active Pharm Ingred/Chems for Further Manuf | 1 |
Most recent refused tirzepatide lines
| Shipment ID | |||||
|---|---|---|---|---|---|
| Oct 29, 2026 | Name not shown | Italy | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | SCS-5299095-7/10003/1 |
| Oct 7, 2026 | SHANGHAI SHUNYI TRADE CO LTD | China | 61PIR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | XXX-0763321-9/1/1 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | XXX-0763336-3/1/2 |
| Sep 28, 2026 | Name not shown | China | 61PCR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | XXX-0763136-5/1/1 |
| Sep 25, 2026 | Name not shown | United States | 61PDY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-2853870-1/10001/1 |
| Sep 22, 2026 | MITSUBISHI TANABE PHARMA CORPORATION . | Japan | 61PCP74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-8179469-5/10002/1 |
| Sep 14, 2026 | BIOAMINO LABS | Germany | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | XXX-0761571-4/1/1 |
| Sep 10, 2026 | ELI LILLY JAPAN | Japan | 61PCL74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9702092-7/10002/1 |
| Sep 8, 2026 | Eli Lilly Italia SPA | Italy | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9744427-5/10002/1 |
| Sep 3, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0976985-1/10002/1A |
| Sep 3, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0976985-1/10002/1B |
| Sep 3, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0976985-1/10002/1C |
| Aug 31, 2026 | Eli Lillyand Company | United States | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0896550-0/10001/1 |
| Aug 19, 2026 | MITSUBISHI TANABE PHARMA CORPORATION . | Japan | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-8049552-6/10002/1 |
| Aug 14, 2026 | Eli Lilly & Company | United States | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0899186-0/10002/1 |
| Jul 31, 2026 | Name not shown | Vietnam | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | SCS-0349383-8/40002/2 |
| Jul 27, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PDL74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9601308-9/10002/1 |
| Jul 27, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PDL74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9601308-9/10002/2 |
| Jul 24, 2026 | CHONGUHAN MEDICAL TECHNOLOGIES | China | 61PDA74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0834622-2/10002/1 |
| Jul 22, 2026 | ELI LILLY AND COMPANY PVT LTD | India | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0437132-3/10002/1 |
The 20 most recent of 201 are shown, with charges, on the GLP-1 import records page and in the CSV download.
All firms and countries: Firms on GLP-1 import records.
FDA NDC Directory listings
FDA’s NDC Directory files read Nov 15, 2026 carry 201 listings naming tirzepatide: NDA (54); BULK INGREDIENT (46); DRUG FOR FURTHER PROCESSING (42); OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (33); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (26). Outsourcing facility listings: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA? Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”
Medicare and Medicaid spending on tirzepatide
Medicare Part D spent $6.34 billion on tirzepatide brands in 2024 (Mounjaro $6.34 billion, Zepbound $387,343), before manufacturer rebates, according to CMS. Pharmacies were reimbursed at least $3.32 billion for tirzepatide products paid through Medicaid nationwide in 2025, across at least 3,140,509 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 53 rows of 194, so these figures are floors.
Medicare Part D, by brand and year
| Mounjaro | Tirzepatide | No data | No data | $144,035,152 | $2,361,384,157 | $6,336,942,641 |
| Zepbound | Tirzepatide | No data | No data | No data | No data | $387,343 |
Medicaid, nationwide, by year
| 2020 | No data |
| 2021 | No data |
| 2022 | at least $34,060,250 |
| 2023 | at least $439,944,750 |
| 2024 | at least $1,205,743,835 |
| 2025 | at least $3,323,545,465 |
| 2026 (Q1) | at least $911,460,172 |
Figures are before manufacturer rebates, as CMS reports them. Every GLP-1 drug, CMS’s caveats and each state: Medicare and Medicaid spending on GLP-1 drugs.
FDA warning letters naming tirzepatide
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Oct 30, 2026 | RonanRx, Inc. dba RonanRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 18, 2026 | Empower Clinic Services, LLC dba Empower Pharmacy | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | TXP Innovations LLC dba Tex Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Royal Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peptide Partners LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Maximus Health, Inc. dba Maximus | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Trinity HealthCare Supply, LLC dba altRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Glow Medispa, LLC dba Mint Med | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Ezra Holdco LLC dba Ezra | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Public Health Solution LLC dba DrMedHealth | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | D&H Medical Services | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Amie Health, Inc. dba Amie | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Altru Telehealth, LLC dba Altru Telehealth | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Eden Health International Inc. dba Eden | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | NativeMed LLC dba NativeMed | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | FitRX, LLC dba AM RX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Momentum Health 360 dba Momentum Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Medica Weight Loss | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Clover Meds LLC dba Clover Meds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Nexlife Inc. dba Nexlife | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Joi and Blokes dba Joi + Blokes | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | VivioMD Group LLC dba VivioMD | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Nexus Health Solutions LLC dba Harper Meds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Nova Vascular LLC dba NOVARX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Ready Med | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | OrderlyMeds LLC dba OrderlyMeds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | HydraMed IV LLC dba HydraMed | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | FITISH | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| May 1, 2026 | Harbin Jixianglong Biotech Co., Ltd. | CGMP/API/Adulterated and Misbranded Drugs | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 14, 2026 | New Life Pharma LLC | CGMP/Adulterated and Unapproved New Drug/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 7, 2026 | ProRx LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Prime Sciences | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Mile High Compounds LLC | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Lovega LLC dba Pink Pony Peptides | Unapproved New Drugs Sold Over the Internet | Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Gram Peptides | Unapproved New Drugs Sold Over the Internet | Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Premium Health Management Inc. dba Premium Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Bliv Wellness LLC dba Bliv | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | BluefitMD | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Aspen Aesthetics dba Fifty 410 | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | FitRX, LLC dba FitRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Genesis Health International Inc. dba Genesis | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Lean Rx, Inc. dba SkinnyRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Kare Solutions, LLC dba Zappy | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Strut Health, LLC dba Strut | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Weightless Medical LLC dba WeightCare | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Viv Health, Inc. dba VIV RX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | PharmaZee | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Good Girl LLC dba GoodGirlRX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Ivim Services LLC dba Ivim | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Join Josie | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Kin Meds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | MaxLife Technologies Inc. dba Maxlife | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Better Health Labs, Inc. dba Measured | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | MEDVi, LLC dba MEDVi | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Newman Clinic, PLLC dba Newman Clinic | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | NewSelf Limited dba NewSelf | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | 24HrDoc, Inc. dba 24HrDoc | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Alan Health Technologies Inc. dba Alan | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Dripgym Mobile Parent, LLC dba Amp Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Belle Health LLC dba Belle | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Zeuss LLC dba Zeuss | False & Misleading Claims/Misbranded (Telehealth) | Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 9, 2026 | Thrive Health and Wellness, LLC dba Thrive Health Solutions | Compounding Pharmacy/Adulterated Drug Products | Tirzepatide | Close-out letter, Aug 6, 2026 | fda.gov |
| Jan 20, 2026 | GenoGenix LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 16, 2026 | Boothwyn Pharmacy, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 1, 2025 | Apothecary Pharma, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Expert Aesthetics | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GenLabMeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Get.Fit.Medical, LLC dba Get.Fit.Medical | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | FWD Care, Inc. dba FWD | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lean Dreams LLC dba LeanDreams | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | ybycmeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Vitals RX | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Tuyo Health, Inc. dba Tuyo Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lovely Meds, Inc. dba Lovely Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lyfe Rx | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | inspire.clinic | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Bioverse, Inc. dba Bioverse | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | SimpleRx | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Elevate Your Wellness LLC, dba Elevated | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | EvoLife Wellness | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Nuvo Life Health Inc. dba Nuvo Life Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | directmeds.com, Inc. dba DirectMeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lumimeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GLP-1 Solution | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | ASN-LABS | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | All American Wellness | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Intimate Rose | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Invigorate Med Spa | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Dr. Gater’s Weight Loss & Wellness | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Remedy Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | EA WORKS Limited Liability Company dba Trust Labs | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Fancy Meds, LLC dba Fancy Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Curex | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Healthon Inc. dba Healthon | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Slendid | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Sprout Health Partners LLC dba Sprout Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Master Pharmaceuticals Group | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | TRYM Health, Inc. dba TRYM Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Reset IV, LLC dba Reset IV | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | eDrugstore | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Healthy Male | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 8, 2025 | Tailstorm Health Inc. dba Medivant Health | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | Close-out letter, Apr 14, 2026 | fda.gov |
| Mar 4, 2025 | ProRx, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 26, 2025 | USApeptide.com | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Prime Vitality, Inc. dba Prime Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Summit Research Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 12, 2024 | Nomida.biz | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 7, 2024 | US Chem Labs | CGMP/Finished Pharmaceuticals/Adulterated | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 7, 2024 | Synthetix Inc. DBA Helix Chemical Supply | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Oct 2, 2023 | www.gorillahealing.com | Finished Pharmaceuticals/Unapproved New Drug/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Recalls naming tirzepatide
| Record | ||||||
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Houston Rx LLC | Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032. | Lack of assurance of sterility. | Class II | Ongoing | D-0040-2027 |
| Sep 24, 2026 | Apothecary Pharma LLC | Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18. | Lack of Assurance of Sterility | Class II | Ongoing | D-0036-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0027-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0030-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0028-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0029-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infus... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0017-2027 |
| Feb 26, 2026 | New Life Pharma LLC | Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04. | Lack of Assurance of Sterility | Class II | Ongoing | D-0395-2026 |
| Feb 26, 2026 | New Life Pharma LLC | Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03. | Lack of Assurance of Sterility | Class II | Ongoing | D-0394-2026 |
| Oct 15, 2025 | ProRx LLC | Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139... | Lack of Assurance of Sterility | Class II | Ongoing | D-0120-2026 |
| Jul 30, 2025 | GenoGenix LLC | Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labe... | Lack of Assurance of Sterility | Class II | Ongoing | D-0092-2026 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do n... | Lack of Processing Controls. | Class II | Ongoing | D-0555-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2mL Multi Dose Vial, Refrigerate, Do no... | Lack of Processing Controls. | Class II | Ongoing | D-0554-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, D... | Lack of Processing Controls. | Class II | Ongoing | D-0558-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 3 x 2 mL Multi Dose Vial, Refrigerate... | Lack of Processing Controls. | Class II | Ongoing | D-0560-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do ... | Lack of Processing Controls. | Class II | Ongoing | D-0556-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do ... | Lack of Processing Controls. | Class II | Ongoing | D-0557-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do ... | Lack of Processing Controls. | Class II | Ongoing | D-0559-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0484-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Tirzepatide/Cyanocobalamin Injectable, 15mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0485-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Tirzepatide Injections, 10mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0482-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Tirzepatide/Cyanocobalamin Injectable, 30mg/1mg/mL (15mg/0.5mg/0.5mL), pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo... | Lack of Assurance of Sterility | Class II | Ongoing | D-0486-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Tirzepatide Injections, 20mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0483-2025 |
| Aug 22, 2024 | ProRx LLC | Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0651-2024 |
| Aug 22, 2024 | ProRx LLC | TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02 | Lack of Assurance of Sterility | Class II | Ongoing | D-0656-2024 |
| Aug 22, 2024 | ProRx LLC | TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0655-2024 |
| Apr 20, 2024 | Revive Rx LLC dba Revive Rx Pharmacy | Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77... | Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionate | Class I | Ongoing | D-0511-2024 |
| May 11, 2023 | Revive Rx LLC dba Revive Rx Pharmacy | Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, N... | Sub-potent Drug | Class II | Ongoing | D-0771-2023 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA Adverse Event Reporting System (FAERS), via openFDA drug event endpoint
- FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Federal Register, June 26, 2026: Extension of Comment Period
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- CMS Medicare Part D Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.